These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37827469)

  • 21. Association between non-alcoholic fatty liver disease and the risk of biliary tract cancers: A South Korean nationwide cohort study.
    Park JH; Hong JY; Kwon M; Lee J; Han K; Han IW; Kang W; Park JK
    Eur J Cancer; 2021 Jun; 150():73-82. PubMed ID: 33892409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.
    Nishihara T; Miyoshi T; Nakashima M; Miki T; Toda H; Yoshida M; Ichikawa K; Osawa K; Yuasa S
    Cardiovasc Diabetol; 2024 May; 23(1):167. PubMed ID: 38730426
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of non-alcoholic fatty liver disease in regional Victoria: a prospective population-based study.
    Roberts SK; Majeed A; Glenister K; Magliano D; Lubel JS; Bourke L; Simmons D; Kemp WW
    Med J Aust; 2021 Jul; 215(2):77-82. PubMed ID: 34028830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between triglyceride-glucose related indices and mortality among individuals with non-alcoholic fatty liver disease or metabolic dysfunction-associated steatotic liver disease.
    Chen Q; Hu P; Hou X; Sun Y; Jiao M; Peng L; Dai Z; Yin X; Liu R; Li Y; Zhu C
    Cardiovasc Diabetol; 2024 Jul; 23(1):232. PubMed ID: 38965572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease.
    Semmler G; Balcar L; Wernly S; Völkerer A; Semmler L; Hauptmann L; Wernly B; Aigner E; Niederseer D; Datz C
    Front Endocrinol (Lausanne); 2023; 14():1244405. PubMed ID: 37842290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non alcoholic fatty liver disease and risk of incident diabetes in subjects who are not obese.
    Sung KC; Seo DC; Lee SJ; Lee MY; Wild SH; Byrne CD
    Nutr Metab Cardiovasc Dis; 2019 May; 29(5):489-495. PubMed ID: 30940491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of liver fibrosis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome.
    Shaji N; Singhai A; Joshi R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?
    Lonardo A; Lugari S; Ballestri S; Nascimbeni F; Baldelli E; Maurantonio M
    Acta Diabetol; 2019 Apr; 56(4):385-396. PubMed ID: 30519965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High prevalence of non-alcoholic fatty liver disease and metabolic risk factors in Guatemala: A population-based study.
    Rivera-Andrade A; Kroker-Lobos MF; Lazo M; Freedman ND; Smith JW; Torres O; McGlynn KA; Groopman JD; Guallar E; Ramirez-Zea M
    Nutr Metab Cardiovasc Dis; 2019 Feb; 29(2):191-200. PubMed ID: 30573307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity.
    Ampuero J; Aller R; Gallego-Durán R; Banales JM; Crespo J; García-Monzón C; Pareja MJ; Vilar-Gómez E; Caballería J; Escudero-García D; Gomez-Camarero J; Calleja JL; Latorre M; Albillos A; Salmeron J; Aspichueta P; Lo Iacono O; Francés R; Benlloch S; Fernández-Rodríguez C; García-Samaniego J; Estévez P; Andrade RJ; Turnes J; Romero-Gómez M;
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1260-1270. PubMed ID: 30353552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fatty liver index as a simple predictor of incident diabetes from the KoGES-ARIRANG study.
    Yadav D; Choi E; Ahn SV; Koh SB; Sung KC; Kim JY; Huh JH
    Medicine (Baltimore); 2016 Aug; 95(31):e4447. PubMed ID: 27495073
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypertension and diabetes mellitus are associated with high FIB-4 index in a health checkup examination cohort without known liver disease.
    Sato S; Kawai H; Sato S; Iwasaki H; Omori M; Kita Y; Ikeda Y; Awatsu T; Murata A; Taniguchi G; Shimada Y; Genda T
    BMC Gastroenterol; 2022 Nov; 22(1):478. PubMed ID: 36411436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of Steatotic Liver Disease Among US Adults with Rheumatoid Arthritis.
    Vassilopoulos A; Kalligeros M; Vassilopoulos S; Shehadeh F; Benitez G; Kaczynski M; Lazaridou I; Promrat K; Wands JR; Mylonakis E
    Dig Dis Sci; 2024 Mar; 69(3):989-1003. PubMed ID: 38183561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonalcoholic Fatty Liver Disease.
    Sweet PH; Khoo T; Nguyen S
    Prim Care; 2017 Dec; 44(4):599-607. PubMed ID: 29132522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Diagnosis and evaluation of metabolic dysfunction associated steatotic liver disease (MASLD)].
    Canivet CM; Faure S
    Rev Med Interne; 2024 Jan; 45(1):41-47. PubMed ID: 38158295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD.
    Suzuki H; Shimose S; Iwamoto H; Niizeki T; Kawaguchi T
    Clin Mol Hepatol; 2024 Apr; 30(2):263-265. PubMed ID: 38246698
    [No Abstract]   [Full Text] [Related]  

  • 38. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PNPLA3 Genotype and Diabetes Identify Patients With Nonalcoholic Fatty Liver Disease at High Risk of Incident Cirrhosis.
    Chen VL; Oliveri A; Miller MJ; Wijarnpreecha K; Du X; Chen Y; Cushing KC; Lok AS; Speliotes EK
    Gastroenterology; 2023 May; 164(6):966-977.e17. PubMed ID: 36758837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease.
    Bessissow T; Le NH; Rollet K; Afif W; Bitton A; Sebastiani G
    Inflamm Bowel Dis; 2016 Aug; 22(8):1937-44. PubMed ID: 27379445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.